# US 11,028,138 B2 · Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,028,138 B2 - Document ID: US11028138B2 - Status: Granted - Kind: B2 - Application number: 15/446,240 - Filed: 2017-03-01 - Published: 2018-01-04 - Granted: 2021-06-08 - Earliest claimed: 2016-07-02 - Applicants: Virongy L.L.C. - Inventors: Yuntao Wu - Web page: https://patentgrep.com/patent/US11028138B2 ## CPC - C07K 14/4716: {Muscle proteins, e.g. myosin, actin} - A61K 38/1719: {Muscle proteins, e.g. myosin or actin} - A61K 47/51: the non-active ingredient being a modifying agent - A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22 - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Compositions and methods for using actin-based peptides to modulate cellular bioactivity, including modulation of cellular susceptibility to intracellular pathogens, such as bacteria and viruses. ## Claims ### Claim 1 An actin-based peptide, comprising an actin core domain and a cell penetration domain, operably linked together by a spacer domain, wherein an N-terminus or C-terminus may have either the actin core domain or the cell penetration domain; and wherein the actin core domain is a B11 core domain having the sequence of YVALDFE, which are the amino acid residues 3-9 of SEQ ID NO:857. ### Claim 2 (depends on 1) The actin-based peptide of claim 1, wherein the actin core domain functions to control viral or bacterial infection of a cell by inhibiting or enhancing viral or bacterial infection or bacterial vector delivery into the cell. ### Claim 3 (depends on 1) The actin-based peptide of claim 1, wherein the actin core domain is labeled with a traceable dye or marker. ### Claim 4 (depends on 1) The actin-based peptide of claim 1, wherein said cell penetration domain is a cell penetration peptide. ### Claim 5 (depends on 1) An actin-based peptide of claim 1, wherein said actin core domain modulates a cellular bioactivity selected from the group consisting of cytoplasmic and nuclear actin dynamics; cell morphology; cell motility and mobility; cell surface receptor density; cell adhesion processes; gene expression; cell division, growth, differentiation, and apoptosis; the processes of endocytosis and exocytosis; smooth and heart muscle cell contraction and relaxation, blood vessel elasticity and capacitance; a process of inflammation; cellular susceptibility to intracellular pathogens, or cellular uptake of chemical compounds, including small and macro molecules, medical drugs, nucleic acids, and proteins. ### Claim 6 (depends on 5) The actin-based peptide of claim 5, wherein said actin-based peptide is labeled with a traceable dye or marker. ### Claim 7 (depends on 1) The actin-based peptide of claim 1, wherein the actin-based peptide comprises the amino acid sequence of SEQ ID NOs: 5, 13, 602-604, 627-630, 649-661, 666-672, 680-701, or 709-723. ### Claim 8 (depends on 1) The actin-based peptide of claim 1, wherein the actin-based peptide is selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 13. ### Claim 9 (depends on 1) The actin-based peptide of claim 1, wherein the actin-based peptide comprises the amino acid sequence of SEQ ID NOs: 602-604 or 627-630. ### Claim 10 (depends on 1) The actin-based peptide of claim 1, wherein the actin-based peptide comprises the amino acid sequence of SEQ ID NOs: 649-661. ### Claim 11 (depends on 1) The actin-based peptide of claim 1, wherein the actin-based peptide comprises the amino acid sequence of SEQ ID NOs: 666-672, 680-701, or 709-723. ### Claim 12 (depends on 1) A kit comprising one or more actin-based peptides of claim 1 and an effective amount of a therapeutic compound, a diagnostic compound, or a compound for modulating cellular activity. ### Claim 13 (depends on 1) A method for controlling viral or bacterial infection, comprising administering an actin-based peptide of claim 1 to a cell, virus, or bacteria, in an amount sufficient to inhibit or enhance infection of said virus or bacteria. ### Claim 14 (depends on 13) The method of claim 13, wherein HIV infection is increased by administering said actin-based peptide to a cell. ### Claim 15 (depends on 1) A method for modulating cellular bioactivity, comprising delivering into a cell one or more actin-based peptides of claim 1 in an amount effective to modulate cellular bioactivity.